Chembio Diagnostics develops and commercializes point-of-care diagnostic tests used for the detection and diagnosis of infectious diseases, including sexually transmitted disease and COVID-19. Co.'s product portfolio is based upon its proprietary DPP technology, a diagnostic platform that provides results in 15 to 20 minutes using fingertip blood, nasal swabs and other sample types. The DPP technology platform addresses the diagnostic test market, which includes infectious diseases, cardiac markers, cholesterol and lipids, and drugs of abuse. The DPP technology platform can provide sensitivity and specificity, multiplexing capabilities, and with the DPP Micro Reader, quantitative results.